Revance Therapeutics Inc (NASDAQ:RVNC) – Research analysts at William Blair boosted their FY2019 earnings per share (EPS) estimates for shares of Revance Therapeutics in a research note issued to investors on Tuesday, November 5th. William Blair analyst T. Lugo now expects that the biopharmaceutical company will post earnings of ($3.80) per share for the year, up from their prior forecast of ($3.88). William Blair has a “Outperform” rating on the stock. William Blair also issued estimates for Revance Therapeutics’ Q4 2019 earnings at ($1.14) EPS, Q1 2020 earnings at ($1.40) EPS, Q2 2020 earnings at ($1.45) EPS, Q3 2020 earnings at ($1.39) EPS, Q4 2020 earnings at ($1.31) EPS and FY2020 earnings at ($5.54) EPS.
Other research analysts have also recently issued reports about the company. BidaskClub raised Revance Therapeutics from a “sell” rating to a “hold” rating in a research note on Wednesday, October 16th. Zacks Investment Research cut Revance Therapeutics from a “buy” rating to a “hold” rating in a research note on Thursday, October 17th. ValuEngine raised Revance Therapeutics from a “sell” rating to a “hold” rating in a research note on Thursday, August 1st. HC Wainwright set a $23.00 price objective on Revance Therapeutics and gave the company a “buy” rating in a research note on Tuesday, October 15th. Finally, Mizuho reissued a “buy” rating and issued a $34.00 target price on shares of Revance Therapeutics in a research note on Tuesday, November 5th. Three investment analysts have rated the stock with a hold rating and eight have assigned a buy rating to the company. The company has a consensus rating of “Buy” and an average price target of $29.88.
Revance Therapeutics (NASDAQ:RVNC) last posted its earnings results on Monday, November 4th. The biopharmaceutical company reported ($0.96) earnings per share (EPS) for the quarter, hitting the consensus estimate of ($0.96). The firm had revenue of $0.05 million for the quarter, compared to the consensus estimate of $0.40 million. Revance Therapeutics had a negative return on equity of 87.59% and a negative net margin of 3,745.97%.
Several hedge funds and other institutional investors have recently bought and sold shares of the stock. HighTower Advisors LLC grew its stake in shares of Revance Therapeutics by 4.6% in the second quarter. HighTower Advisors LLC now owns 27,200 shares of the biopharmaceutical company’s stock worth $352,000 after purchasing an additional 1,200 shares during the last quarter. Zurcher Kantonalbank Zurich Cantonalbank lifted its holdings in Revance Therapeutics by 86.1% in the third quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 2,727 shares of the biopharmaceutical company’s stock worth $35,000 after buying an additional 1,262 shares during the period. Nottingham Advisors Inc. lifted its holdings in Revance Therapeutics by 20.0% in the third quarter. Nottingham Advisors Inc. now owns 12,004 shares of the biopharmaceutical company’s stock worth $156,000 after buying an additional 2,000 shares during the period. FNY Investment Advisers LLC purchased a new stake in Revance Therapeutics in the second quarter worth about $37,000. Finally, Rhumbline Advisers lifted its holdings in Revance Therapeutics by 5.1% in the third quarter. Rhumbline Advisers now owns 66,654 shares of the biopharmaceutical company’s stock worth $867,000 after buying an additional 3,258 shares during the period. 98.62% of the stock is currently owned by institutional investors.
About Revance Therapeutics
Revance Therapeutics, Inc, a clinical-stage biotechnology company, engages in the development, manufacture, and commercialization of novel neuromodulators for various aesthetic and therapeutic indications. The company's lead drug candidate is DaxibotulinumtoxinA for injection (DAXI), which is in phase III clinical trials to treat glabellar (frown) lines and cervical dystonia; and in phase II clinical trials for the treatment of plantar fasciitis, adult upper limb spasticity, and chronic migraine.
See Also: What is the quiet period?
Receive News & Ratings for Revance Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Revance Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.